Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.
about
Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activityCognitive Dysfunction, Affective States, and Vulnerability to Nicotine Addiction: A Multifactorial PerspectivenAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Negative affective states and cognitive impairments in nicotine dependenceNicotine ameliorates schizophrenia-like cognitive deficits induced by maternal LPS exposure: a study in rats.Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Mouse models for studying genetic influences on factors determining smoking cessation success in humans.Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice.The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in ratsNicotine, Auditory Sensory Memory, and sustained Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait.Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humansAcute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine.Smoking restores impaired LTD-like plasticity in schizophrenia: a transcranial direct current stimulation study.Cigarette smoking is associated with thinner cingulate and insular cortices in patients with severe mental illnessMood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral statesAlpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia.COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokersAre cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study.Impact of tobacco regulation on animal research: new perspectives and opportunitiesReward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.Comparison of the effectiveness of Conners' CPT and the CPT-identical pairs at distinguishing between smokers and nonsmokers with schizophrenia.A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia.Baseline impulsive choice predicts the effects of nicotine and nicotine withdrawal on impulsivity in rats.Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.Neuromodulation by acetylcholine: examples from schizophrenia and depression.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactatioNicotine self-administration reverses cognitive deficits in a rat model for schizophrenia.1,3-diphenylpropan-1-ones as allosteric modulators of α7 nACh receptors with analgesic and antioxidant properties.Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree?At-Line Cellular Screening Methodology for Bioactives in Mixtures Targeting the α7-Nicotinic Acetylcholine Receptor.Nerve terminal nicotinic acetylcholine receptors initiate quantal GABA release from perisomatic interneurons by activating axonal T-type (Cav3) Ca²⁺ channels and Ca²⁺ release from stores.Nicotine restores Wt-like levels of reelin and GAD67 gene expression in brain of heterozygous reeler mice.Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242.Nicotine exposure during adolescence: cognitive performance and brain gene expression in adult heterozygous reeler mice.Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study.Altered brain functional networks in heavy smokers.Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach.Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility.
P2860
Q26991451-E6EF5D49-5F4E-482A-8415-963D210E2DBDQ28071876-CE6DDD63-1F0B-4B30-8A91-838A86BBF871Q30362464-45C606DA-5AE1-45B5-860B-E6BD628CB0D8Q30371220-9BB6F31D-0DB8-45A0-AA15-DA932F92DA13Q30371377-B65B6819-0926-4E08-A194-EAA602143B6FQ30428422-EFCE6B28-7FA5-4351-9A64-9A4D6E99C72FQ30432964-524DC0DF-56CA-42FE-87C2-57A82B9D67A8Q30443234-CCE1F293-C132-4803-B7BD-A7EC06DBB9CCQ30455777-BCBC0EA9-BBD2-446C-B0E3-7B174B45DC44Q30462575-8F677233-08C2-4E81-8EB0-5D2736251872Q30597187-26209483-69E7-4439-B20A-EE5B944E4ED9Q33768017-2618A865-B60F-464E-B2CA-417014F120E6Q34426718-8F6F4574-DFD4-46CB-A359-F3EDDA935F32Q35089413-E30F724B-60BC-40C0-A6F1-DC859C3F330DQ35772079-9DEDE490-3731-47AA-9E3A-C93E0B152634Q35802079-CB9BC634-F28D-499D-9894-F9F1150A07AEQ35837691-A02702B6-0E66-4B80-9194-BEFEB6F1A2A4Q35887978-EC887F83-CEB4-4ED5-9E07-704058B6343BQ36439996-5A7B29AE-A2C3-4D7D-A9FE-1DC127699C05Q36727831-6F677FF2-294A-45BC-915D-CE6B7E8A9E08Q36935148-E51FB2EC-1401-4961-A35D-6EDDB412780AQ37067243-66CCEC7C-3D4B-4902-9336-60E966D70A30Q37127723-4BB11B2D-414C-4CB7-8D3F-8B3F62D098ABQ37381476-68201864-EF51-4284-A5A5-5D99983A1A7DQ38171876-0F06EA3E-BD9A-4A7C-8810-27AA4BAC4739Q38225161-2A60D6E3-C5BE-4F48-A982-CF770BAFAC55Q38395937-FD4660B6-26C1-4F51-8702-DE0A3643CE6BQ38789911-09A579D8-E71A-4A71-BD27-563B2CA6D2FCQ38869450-E1CAF4FD-7AEA-4F0C-8F5D-92AF41E10592Q39261867-07B89EBE-F405-4C40-8C5D-0DC8B3AC847FQ39352539-53161FE7-F198-4B3B-BBF5-61151ED8ADADQ40136029-0BF3D3B2-65FB-44C6-9DDF-6B27AD772E4EQ42172411-02DB201A-D2F9-4C3E-8392-8C247D137D1CQ46314942-176A735A-2D2E-4185-8D06-9E9B15EFD65BQ47789718-0792F4D5-9EC9-4D93-8D4C-031EC4710EA6Q47819976-51336227-2064-49F6-A6AD-1461A41B51EBQ48559497-5FEC5102-25F5-475B-844A-EDA9041DB1F6Q48697197-4A8D66A0-19E2-47DC-A53E-9DAC37360BBFQ49870570-1A89C83A-F224-4436-9992-B210A333D90AQ50600844-BA87108D-705F-4AD8-B947-87DF8C827111
P2860
Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Schizophrenia and tobacco smok ...... associated cognitive deficits.
@en
type
label
Schizophrenia and tobacco smok ...... associated cognitive deficits.
@en
prefLabel
Schizophrenia and tobacco smok ...... associated cognitive deficits.
@en
P2860
P1433
P1476
Schizophrenia and tobacco smok ...... associated cognitive deficits.
@en
P2093
Athina Markou
Manoranjan S D'Souza
P2860
P304
P356
10.1016/J.NEUROPHARM.2011.01.044
P577
2011-02-01T00:00:00Z